EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Influence of the COVID-19 Pandemic in NK Cell Subpopulations from CML Patients Enrolled in the Argentina Stop Trial

María Belén Sanchez, Bianca Vasconcelos Cordoba, Carolina Pavlovsky, Beatriz Moiraghi, Ana Ines Varela, Isabel Giere, Mariana Juni, Nicolas Flaibani iD, José Mordoh, Julio Cesar Sanchez Avalos, Estrella Mariel Levy iD, Michele Bianchini

Cells · 2025

DOI: 10.3390/cells14090628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von María Belén Sanchez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigaciones Oncológicas-Fundación Cáncer FUCA, Buenos Aires 1426, Argentina. Hauptthemen laut MEDLINE: Killer Cells, Natural, COVID-19, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Cáncer (FUCA); ANPCyT PICT-2021-I-A-00283; Fundación SALES, Fundación Pedro Mosoteguy; Instituto Nacional del Cáncer (INC), FUNDALEU, Novartis Argent…, Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment-free remission (TFR) is a key therapeutic goal for chronic myeloid leukemia (CML) patients in deep molecular response (DMR). While predicting patient outcome remains challenging, different NK cell populations seem crucial. We conducted an immunological sub-study from the Argentina Stop Trial (AST), including 46 patients in 2019 (AST I) and 35 new patients between 2022 and 2023 (AST II). To characterize NK cell subsets in patients attempting TFR, peripheral blood mononuclear cell samples were collected before stopping treatment and phenotype and functional characteristics were assessed by flow cytometry. Non-relapsing patients from AST I exhibited NK cell subpopulations with cytomegalovirus-related memory features, high expression of cytotoxicity markers, and robust functionality. Remarkably, though clinical variables were very similar between cohorts, significant immune differences were observed. NK cell percentage and CD16 and CD57 receptor expression levels were significantly reduced in AST II (p = 0.0051; p = 0.0222; p = 0.0033, respectively), whereas NKp46, NKp44 and PD-1 expression levels were significantly increased (p = 0.0081; p < 0.0001; p < 0.0001, respectively). NK cells from AST II patients demonstrated higher overall functionality and more memory-like subpopulations, characterized mainly by the expression of CD57, NKG2C, NKp30 and NKp46 receptors among CD56dim NK cells, also with enhanced functional performance. However, in AST II, we were unable to report an association with clinical outcome. Given the enrollment time of both cohorts and that they appear to be clinically homogeneous, we consider that COVID could be impacting the immune landscape; accordingly, serum samples from AST II, but not AST I, confirmed the presence of anti-SARS-CoV-2 IgG. The influence of the COVID pandemic and the different vaccine platforms on NK cells cannot be underestimated when evaluating the role of the immune system in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalCOVID-19Leukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansArgentinaMaleFemaleMiddle AgedAdultAgedSARS-CoV-2Pandemics

Stichwörter der Autor:innen

COVIDNK cellschronic myeloid leukemiatreatment-free remission

Autor:innen und Institutionen

  • Centro de Investigaciones Oncológicas-Fundación Cáncer FUCA, Buenos Aires 1426, Argentina.
  • Fundación para Combatir la Leucemia (FUNDALEU), Buenos Aires 1114, Argentina.
  • Hospital José María Ramos Mejía, Buenos Aires 1221, Argentina.
  • Laboratorio de Evolución, Facultad de Ciencias Exactas y Naturales (FCEN-UBA), Instituto de Genética, Ecología y Evolución de Buenos Aires (IEGEBA), Buenos Aires 1428, Argentina.
  • Instituto Alexander Fleming, Buenos Aires 1426, Argentina.

ORCID-Profile: Nicolas Flaibani, Estrella Mariel Levy

Förderung

  • Fundación Cáncer (FUCA); ANPCyT PICT-2021-I-A-00283; Fundación SALES, Fundación Pedro Mosoteguy; Instituto Nacional del Cáncer (INC), FUNDALEU, Novartis Argent…
  • Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT)

Zitieren

APA

Sanchez, M. B., Cordoba, B. V., Pavlovsky, C., Moiraghi, B., Varela, A. I., Giere, I., Juni, M., Flaibani, N., Mordoh, J., Avalos, J. C. S., Levy, E. M., & Bianchini, M. (2025). The Influence of the COVID-19 Pandemic in NK Cell Subpopulations from CML Patients Enrolled in the Argentina Stop Trial. Cells. https://doi.org/10.3390/cells14090628

Vancouver

Sanchez MB, Cordoba BV, Pavlovsky C, Moiraghi B, Varela AI, Giere I, et al. The Influence of the COVID-19 Pandemic in NK Cell Subpopulations from CML Patients Enrolled in the Argentina Stop Trial. Cells. 2025. doi:10.3390/cells14090628

BibTeX
@article{Sanchez2025,
  author = {Sanchez, María Belén and Cordoba, Bianca Vasconcelos and Pavlovsky, Carolina and Moiraghi, Beatriz and Varela, Ana Ines and Giere, Isabel and Juni, Mariana and Flaibani, Nicolas and Mordoh, José and Avalos, Julio Cesar Sanchez and Levy, Estrella Mariel and Bianchini, Michele},
  title = {The Influence of the COVID-19 Pandemic in NK Cell Subpopulations from CML Patients Enrolled in the Argentina Stop Trial},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14090628}
}
Kostenlos starten →